NCT04377945View on ClinicalTrials.gov

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions
DyskinesiasParkinson Disease
Interventions
DRUG

Part 1, JM-010 component Group A

JM-010 component Group A

DRUG

Part 1, JM-010 component Group B

JM-010 component Group B

DRUG

Part 1, JM-010 component Group C

JM-010 component Group C

DRUG

Part 1, Placebo Group

Placebo Group

DRUG

Part 2, JM-010 combination Group A

JM-010 combination Group A

DRUG

Part 2, JM-010 combination Group B

JM-010 combination Group B

DRUG

Part 2, JM-010 component Group C

JM-010 component Group C

DRUG

Part 2, Placebo Group

Placebo Group

Trial Locations (2)

33165

Bukwang Investigator site, Miami

48201

Bukwang Investigator site, Detroit

Sponsors
All Listed Sponsors
lead

Bukwang Pharmaceutical

INDUSTRY

NCT04377945 - Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components | Biotech Hunter | Biotech Hunter